Skip to content
ResistanceBio logo

ResistanceBio

ResistanceBio is a YC Winter 2019 (W19) company. Based in Menlo Park, CA, USA; Overland, MO, USA. Team of 15.

  • AI-powered Drug Discovery

About ResistanceBio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

ResistanceBio builds AI-driven drug discovery tools targeting cancer drug resistance. The platform helps researchers and pharmaceutical teams identify why tumors stop responding to treatment and find new therapeutic strategies to overcome it, replacing slow, largely manual preclinical analysis workflows.

From the Y Combinator listing

How ResistanceBio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

We solve drug resistance for cancer

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Menlo Park, CA, USA; Overland, MO, USA
Team size
15
Status
Inactive
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works